These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16846774)

  • 21. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy of advanced ovarian cancer: current status and future directions.
    Ozols RF; Vermorken JB
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-1-S2-9. PubMed ID: 9045324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carboplatin versus cisplatin in ovarian cancer.
    Alberts DS
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology.
    Zinner RG; Saxman SB; Peng G; Monberg MJ; Ortuzar WI
    Clin Lung Cancer; 2010 Sep; 11(5):352-7. PubMed ID: 20837462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overstated conclusions of a pooled analysis of bevacizumab in colon cancer.
    Goffin JR; Talavera JR
    J Clin Oncol; 2006 Jan; 24(3):528-9; author reply 529-30. PubMed ID: 16421433
    [No Abstract]   [Full Text] [Related]  

  • 27. New drugs for ovarian cancer.
    Kaye SB
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):91-3. PubMed ID: 18347558
    [No Abstract]   [Full Text] [Related]  

  • 28. Another confirmation of the inactivity of topotecan in ovarian cancer.
    McGuire WP
    J Natl Cancer Inst; 2010 Oct; 102(20):1523-4. PubMed ID: 20937989
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
    Patel JD; Bonomi P; Socinski MA; Govindan R; Hong S; Obasaju C; Pennella EJ; Girvan AC; Guba SC
    Clin Lung Cancer; 2009 Jul; 10(4):252-6. PubMed ID: 19632943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH
    Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer.
    O'Shaughnessy JA; Brufsky AM
    Clin Breast Cancer; 2008 Aug; 8(4):370-3. PubMed ID: 18757267
    [No Abstract]   [Full Text] [Related]  

  • 32. In focus: bevacizumab for renal cell carcinoma.
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
    [No Abstract]   [Full Text] [Related]  

  • 33. Successful treatment with weekly paclitaxel and carboplatin combined with trastuzumab in a patient with heavily pretreated metastatic breast cancer.
    Kikuchi Y; Takano M; Kudoh K; Kita T; Sato K
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):189-91. PubMed ID: 18778887
    [No Abstract]   [Full Text] [Related]  

  • 34. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
    Goulart B; Ramsey S
    Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?
    Eskens FA; Sleijfer S
    Eur J Cancer; 2008 Nov; 44(16):2350-6. PubMed ID: 18789679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials.
    Lorusso D; Mainenti S; Ferrandina G; Scambia G
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):987-91. PubMed ID: 20645686
    [No Abstract]   [Full Text] [Related]  

  • 37. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel plus carboplatin in the treatment of ovarian cancer.
    Ozols RF
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):84-9. PubMed ID: 10190787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.